BERWYN, Pennsylvanie–(BUSINESS WIRE)– Nordic Group B.V., par l’entremise de sa filiale Nordic Pharma, Inc. (U.S.), poursuit l’introduction du gel canaliculaire LACRIFILL®, une thérapie novatrice contre la sécheresse oculaire, durant le congrès 2024 …
Author: Business Wire
Intraocular Lens Injector Global Market Report 2024, Featuring Profiles of Key Companies Alcon, Johnson & Johnson Vision, Bausch + Lomb, HOYA, STAAR Surgical, Nidek, Topcon, SIFI and More – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Intraocular Lens Injector Market (2024 Edition): Market Size, Trends, Opportunities and Forecast by Product Type, End-User, Technology, Region, By Country: 2020-2030” report has been added to ResearchAndMarkets.com’…
Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Continues Its Introduction of LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye, During American Academy of Ophthalmology (AAO) 2024
BERWYN, Pa.–(BUSINESS WIRE)–Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., launched LACRIFILL Canalicular Gel, a novel therapy for dry eye in the U.S. in April and will continue its introduction to leading ophthalmologists during AAO 2024. L…
ModMed Showcases the Latest in Advanced Solutions for Ophthalmology Practices at AAO 2024
BOCA RATON, Fla.–(BUSINESS WIRE)–ModMed® announces its participation in the American Academy of Ophthalmology (AAO) 2024 conference on October 19-21 in Chicago.
Warby Parker to Announce Third Quarter 2024 Financial Results November 7, 2024
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the third quarter ended September 30, 2024 will be released before…
GenSight Biologics Announces LUMEVOQ® Scientific Updates at AAO 2024
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central …
GenSight Biologics annonce des communications scientifiques sur LUMEVOQ® au Congrès 2024 de l’AAO
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour les maladies neurod…
Horizon Surgical Systems Raises $30 Million in Series A Financing
MALIBU, Calif.–(BUSINESS WIRE)–Horizon Surgical Systems, Inc., a privately-held, micro-robotics company advancing microsurgery with automated AI-enabled robotics, announced the close of a $30M Series A financing. The financing was led by ExSight Vent…
Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that t…
Eye Health America and Verséa Ophthalmics, Inc. Enter Into a Preferred Partnership to Support Management of Ocular Surface Disease and Ocular Surgery
GREENVILLE, S.C. & TAMPA, Fla.–(BUSINESS WIRE)– #biovance–Eye Health America and Verséa Ophthalmics, Inc. Enter Into a Preferred Partnership to Support Management of Ocular Surface Disease and Ocular Surgery.
eternalHealth Unveils 2025 Medicare Advantage Plans Focusing on Affordable, High Quality Healthcare and Expanded Coverage
BOSTON–(BUSINESS WIRE)– #Healthcare–eternalHealth, a leading health insurance in Massachusetts and Arizona, announced its 2025 Medicare Advantage plans earlier this week. In a year where Medicare Beneficiaries are looking for stability, eternalHealt…
Sapio Sciences Enhances Bioanalysis LIMS and ELN with Advanced Immunogenicity Capabilities
BALTIMORE–(BUSINESS WIRE)–Sapio Sciences, the science-aware™ lab informatics platform, today announced the addition of new immunogenicity bioanalysis features to its industry-leading lab informatics platform. These new capabilities in the Sapio LIMS …
Alcon Innovations on Display at AAO 2024 Demonstrate Efficiency and Performance
FORT WORTH, Texas–(BUSINESS WIRE)–Alcon Innovations on Display at AAO 2024 Demonstrate Efficiency and Performance
FDA Grants Clearance for SPECTRALIS Flex Module, Expanding Access to Advanced Multimodal Ophthalmic Imaging for Underserved Patients
FRANKLIN, Mass.–(BUSINESS WIRE)–Heidelberg Engineering, a global leader in ophthalmic imaging and healthcare data solutions, announces FDA clearance of the SPECTRALIS® Flex Module. This innovative, multimodal, diagnostic imaging-only platform is uniq…
EyeCare Partners Looks Ahead Towards Latest Ophthalmology Breakthroughs at the American Academy of Ophthalmology (AAO) 2024 in Chicago
ST. LOUIS–(BUSINESS WIRE)–EyeCare Partners (ECP) announced its doctors will share key data and innovation at the upcoming annual American Academy of Ophthalmology meeting.
Haag-Streit Offers “Sneak Preview” of the New METIS Ophthalmic Microscope System at AAO 2024
CHICAGO–(BUSINESS WIRE)–Haag-Streit, a global leader in ophthalmic medical devices, is proud to introduce METIS, its cutting-edge ophthalmic microscope system, at the upcoming American Academy of Ophthalmology (AAO) 2024 meeting in Chicago. This snea…
Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced t…
Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that i…
Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has approved the enVist…
Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
NASHVILLE, Tenn.–(BUSINESS WIRE)–Melt Pharmaceuticals, Inc. (“Melt”), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced the dosing of the last patient in its pivotal Phase 3 study evaluating …